- Conditions
- Glioblastoma (GBM)
- Interventions
- MT-125
- Drug
- Lead sponsor
- Myosin Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1897–1920
of 5,570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
- Interventions
- MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
- Drug
- Lead sponsor
- Horng Chen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Amprenavir
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 24
- States / cities
- Berkeley, California • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, chemotherapy, efaproxiral, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 6 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer, Triple Negative Breast Cancer
- Interventions
- DKY709, PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more
- Conditions
- HIV Infections
- Interventions
- Fosamprenavir, Lopinavir/Ritonavir, Ritonavir, Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Atlanta, Georgia + 7 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
- Interventions
- KFA115, pembrolizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Electronic Cigarette Use, Cigarette Use, Electronic, Tobacco Use, Tobacco Smoking
- Interventions
- Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS, Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette, Tobacco/Nicotine Abstention, Usual Brand of cigarettes
- Other
- Lead sponsor
- Juul Labs, Inc.
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • St Louis, Missouri + 2 more
- Conditions
- Healthy Volunteer, Cystic Fibrosis
- Interventions
- PTI-801, Placebo, PTI-808
- Drug
- Lead sponsor
- Proteostasis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab pegol
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 36
- States / cities
- Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Regorafenib in combination with pembrolizumab, Loco-regional therapy
- Drug · Procedure
- Lead sponsor
- Translational Research in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Recurrent Breast Cancer, Metastatic Breast Cancer
- Interventions
- Ruxolitinib, Paclitaxel
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- SX-682, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Syntrix Biosystems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 6
- States / cities
- Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- CRLX101, Bevacizumab, Standard of Care (Investigator Choice)
- Drug
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 38
- States / cities
- La Jolla, California • Los Angeles, California • Denver, Colorado + 33 more
- Conditions
- Lung Cancer, Non-Small Cell Lung Cancer
- Interventions
- BMS-986205, Nivolumab, Chemotherapy
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- San Diego, California • Fort Myers, Florida • Jacksonville, Florida + 16 more
- Conditions
- Major Depressive Disorder
- Interventions
- Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Neoplasms
- Interventions
- PF-06647020 Q3W, fluconazole, PF-06647020 Q2W, PF-06647020 combined with Avelumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 7 more
- Conditions
- Epitheliod Malignant Pleural Mesothelioma
- Interventions
- Photodynamic Therapy, Radical Pleurectomy, Chemotherapy, Photofrin 2.0 mg/kg
- Radiation · Procedure · Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Philadelphia, Pennsylvania
- Conditions
- Cancer,, Solid Tumors, Advanced Solid Malignancies
- Interventions
- AZD6918, gemcitabine, pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Nashville, Tennessee
- Conditions
- HIV Infections
- Interventions
- atazanavir/ritonavir, lopinavir/ritonavir
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Osteo Arthritis Knee, Arthritis
- Interventions
- Sustained Acoustic Device with 1% Diclofenac patch
- Combination Product
- Lead sponsor
- ZetrOZ, Inc.
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Dryden, New York
- Conditions
- Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
- Interventions
- Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2, Talazoparib Phase 2
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 38
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 12 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 55
- States / cities
- Jasper, Alabama • Mobile, Alabama • Mesa, Arizona + 47 more